10.2 Cervical Cancer Screening & ASCCP Algorithms

Pathophysiology & Virology of Cervical Neoplasia

Virtually all cervical malignancies (>99%) are etiologically linked to persistent mucosal infection with oncogenic high-risk Human Papillomavirus (hrHPV) types:

• Viral Subtypes: HPV types 16 and 18 account for approximately 70% of invasive cervical carcinomas and 50% of cervical intraepithelial neoplasia grade 3 (CIN 3) lesions globally. Non-16/18 high-risk types (such as 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) account for the remaining 20% to 30%. Low-risk HPV types (predominantly 6 and 11) cause benign anogenital condylomata acuminata and transient low-grade dysplasias, but possess no oncogenic potential.
• Molecular Mechanisms of Oncogenesis: High-risk HPV genomes integrate into host cellular DNA, leading to constitutive over-expression of two potent viral oncoproteins:
  1. E6 Oncoprotein: Binds to host cellular p53 tumor suppressor protein, recruiting E6-associated protein (E6AP) ubiquitin ligase to trigger targeted proteasomal degradation of p53. This halts apoptosis in cells harboring DNA damage.
  2. E7 Oncoprotein: Binds to and phosphorylates the retinoblastoma protein (pRb), disrupting the pRb-E2F complex. Unbound E2F transcription factors enter the nucleus, forcing continuous G1-to-S phase cell cycle transition and driving unregulated cellular proliferation.
• Natural History & Viral Clearance: In adolescents and young adults, HPV infection is an endemic, sexually acquired condition with a lifetime cumulative incidence exceeding 80%. However, in immunocompetent hosts younger than 30, 80% to 90% of incident HPV infections are spontaneously cleared or suppressed to undetectable levels by cell-mediated immunity within 12 to 24 months. Neoplastic transformation from transient viral infection to precancerous CIN 3 requires persistent hrHPV infection over years to decades.

---

USPSTF Cervical Cancer Screening Recommendations by Age Group

The USPSTF provides clear, age-stratified guidelines for cervical cancer screening in asymptomatic, average-risk individuals with a cervix:

1. Age <21 Years: Screening Strictly Contraindicated (USPSTF Grade D)

• Regardless of the age of coital debut, number of sexual partners, or other behavioral risk factors, screening is not recommended in individuals younger than 21.
• Rationale: Invasive cervical carcinoma is extraordinarily rare in this demographic (<1 to 2 cases per 1,000,000). Although HPV infection rates are high in sexually active adolescents, virtually all resulting dysplastic changes represent transient, self-limiting CIN 1 that regresses spontaneously. Screening adolescents produces extreme harm through overtreatment: excisional cervical procedures (LEEP/cold knife conization) permanently compromise cervical tensile integrity, dramatically increasing future risks of cervical insufficiency, second-trimester spontaneous abortion, and preterm premature rupture of membranes (PPROM).

2. Age 21 to 29 Years: Cytology Alone Every 3 Years (USPSTF Grade A)

• Recommended Modality: Cervical cytology (liquid-based or conventional Pap smear) alone every 3 years.
• Strict Rule on hrHPV Testing: High-risk HPV screening (either as primary standalone HPV testing or as co-testing with cytology) is strictly NOT recommended for routine screening in women aged 21 to 29. Because transient hrHPV infections are exceedingly common in this cohort, routine HPV testing generates high rates of false-positive results that prompt unnecessary colposcopies and emotional distress without improving cancer prevention. (Reflex HPV testing is permitted only for triaging atypical squamous cells of undetermined significance [ASC-US]).

3. Age 30 to 65 Years: Three Equivalent Grade A Strategies (USPSTF Grade A)

For average-risk women aged 30 to 65 years, the USPSTF endorses three acceptable screening strategies:

1. Cervical Cytology Alone Every 3 Years: Reliable, time-tested strategy with excellent specificity.
2. High-Risk HPV (hrHPV) Alone Every 5 Years: Performed using an FDA-approved primary hrHPV screening assay. Primary hrHPV testing exhibits higher clinical sensitivity (>90%) for high-grade cervical precancer (CIN 3+) compared to single-timepoint cytology (50–70%), permitting safe extension of screening intervals to 5 years.
3. Cervical Cytology + hrHPV Co-Testing Every 5 Years: Combines cytologic morphological examination with molecular viral detection.

Clinical Guideline Nuance: The American Cancer Society (ACS) guidelines preferentially recommend primary hrHPV testing alone every 5 years beginning at age 25. However, on the ABFM board examination, the USPSTF guidelines are the primary benchmark: screening begins at age 21 with cytology alone every 3 years, and hrHPV testing is incorporated only beginning at age 30.

---

Discontinuing Screening: Age 65 Stopping Rules & Hysterectomy Status

The Age 65 Cessation Criteria (USPSTF Grade D)

Routine cervical cancer screening should be discontinued at age 65 provided the patient fulfills both of the following prerequisites:

1. Documented Adequate Prior Negative Screening:
   • Three consecutive negative cervical cytology results, OR
   • Two consecutive negative hrHPV or co-test results,
   • Within the preceding 10 years, with the most recent test performed within the last 5 years.
2. Absence of High-Grade Precancer History:
   • No history of CIN 2, CIN 3, or adenocarcinoma in situ (AIS) within the preceding 20 years.

The 20-Year Rule for Prior CIN 2+: If a patient has a documented historical diagnosis of CIN 2, CIN 3, or AIS, routine cervical screening must continue for at least 20 years from the date of histologic regression or surgical treatment, even if that surveillance timeline extends well beyond age 65 (e.g., a woman treated for CIN 3 at age 52 must continue routine screening until at least age 72).

Screening Following Hysterectomy

• Total Hysterectomy for Benign Disease (USPSTF Grade D): In women who have undergone a complete surgical removal of both the uterine corpus and the cervix for benign conditions (such as leiomyomas, adenomyosis, endometriosis, or pelvic organ prolapse) and who have no historical diagnosis of CIN 2, CIN 3, AIS, or cervical cancer, routine screening (vaginal cuff cytology) is permanently discontinued.
• Supracervical Hysterectomy: In women whose cervix remains anatomically intact (subtotal or supracervical hysterectomy), routine cervical screening must continue according to standard age-based recommendations.
• Hysterectomy with History of CIN 2, CIN 3, or AIS: In women who underwent total hysterectomy but have a history of high-grade precancer, the vaginal cuff remains vulnerable to HPV-mediated vaginal intraepithelial neoplasia (VaIN). Routine vaginal cuff screening must continue for at least 20 years following the date of treatment.

---

The 2019 ASCCP Consensus Guidelines: Risk-Based Management

In 2019, the American Society for Colposcopy and Cervical Pathology (ASCCP), in partnership with the National Cancer Institute (NCI), completely revamped cervical management from historical result-based algorithms to a modern quantitative risk-based framework.

The Foundational Principle: "Equal Management for Equal Risk"

Clinical management is dictated by a patient's calculated risk of underlying CIN 3+ (the surrogate for cervical cancer risk), rather than the isolated cytologic result. Risk estimates integrate current screening results (cytology and HPV status), prior screening history, and HPV genotyping.

Master ASCCP Clinical Action Thresholds

---

Algorithmic Management of Specific Cytologic Abnormalities

1. Atypical Squamous Cells of Undetermined Significance (ASC-US)

• Preferred Triaging Strategy: Reflex high-risk HPV testing from the liquid-based cytology vial.
• If hrHPV is Positive: Immediate CIN 3+ risk is approximately 4.5% (surpassing the 4.0% colposcopy threshold). Management: Immediate Colposcopy.
• If hrHPV is Negative: 5-year CIN 3+ risk is <0.5%. Management: Defer colposcopy; resume routine screening (repeat co-test in 3 years).
• Special Population (Age 21 to 24 Years): In young women aged 21 to 24, HPV prevalence is high and regression rates exceed 80%. If cytology reveals ASC-US (regardless of HPV status) or LSIL, repeat cervical cytology in 12 months; colposcopy is deferred unless abnormality progresses to HSIL/ASC-H or persists for 2 consecutive years.

2. Low-Grade Squamous Intraepithelial Lesion (LSIL)

• In women aged >=25 years:
  • If hrHPV is positive or untested: Immediate CIN 3+ risk is approximately 4.3%. Management: Immediate Colposcopy.
  • If hrHPV is negative (on concurrent co-test): Immediate CIN 3+ risk is only 1.1% (well below the 4.0% threshold). Management: Repeat co-testing in 1 year; defer immediate colposcopy.
• In women aged 21 to 24 years: Repeat cytology in 12 months.

3. Atypical Squamous Cells, Cannot Exclude High-Grade (ASC-H)

• Represents a cytologic pattern with high suspicion for underlying high-grade precancer (underlying CIN 2/3 prevalence is 12% to 25%).
• Management: Immediate Diagnostic Colposcopy for all patients regardless of HPV status. Reflex HPV testing cannot be used to triage ASC-H.

4. High-Grade Squamous Intraepithelial Lesion (HSIL)

• Carries an immediate CIN 3+ risk between 25% and 60%.
• Management in non-pregnant patients aged >=25 years:
  • Expedited Treatment (LEEP / Cold Knife Conization) without prior biopsy is acceptable and preferred for patients with completed childbearing or high-risk HPV 16/18 positivity.
  • Alternatively, diagnostic colposcopy with endocervical assessment is acceptable.
• In patients aged 21 to 24 years: Immediate diagnostic colposcopy is mandatory; expedited excisional treatment without biopsy is contraindicated.

5. Atypical Glandular Cells (AGC)

• Represents a perilous cytologic finding reflecting potential neoplasia of the endocervical canal or endometrium (underlying pathology includes adenocarcinoma in situ [AIS], invasive cervical adenocarcinoma, and endometrial adenocarcinoma).
• Initial Management for ALL Patients with AGC (AGC-NOS, AGC favor neoplastic):
  • Immediate Colposcopy with Endocervical Curettage (ECC).
• Mandatory Endometrial Biopsy (EMB) Indications:
  • All patients aged >=35 years with AGC.
  • Patients aged <35 years with clinical risk factors for endometrial neoplasia: unexplained abnormal uterine bleeding, chronic anovulation (PCOS), morbid obesity (BMI >=35), diabetes mellitus, or tamoxifen therapy.

6. HPV Genotype 16 or 18 Positivity with Normal Cytology (NILM)

• HPV 16 and 18 possess extreme oncogenic velocity and are responsible for the vast majority of aggressive cervical adenocarcinomas that evade cytologic exfoliation.
• If a screening co-test reveals NILM (Negative for Intraepithelial Lesion or Malignancy) but HPV 16 or HPV 18 is positive, the immediate CIN 3+ risk is 4.1% to 8.0% (exceeding the 4.0% threshold).
• Management: Immediate Diagnostic Colposcopy. Deferring evaluation to 1-year surveillance is dangerous and unacceptable.

---

Special Clinical Populations: Pregnancy & Immunosuppression

Cervical Evaluation During Pregnancy

• Physiological Changes: High gestational estrogen levels induce marked cervical stromal hypervascularity, eversion of the squamocolumnar junction (physiologic ectropion), stromal softening, and exuberant decidual transformation that can mimic invasive neoplasia.
• Colposcopy Safety: Diagnostic colposcopy is completely safe during pregnancy and should be performed by an experienced clinician for high-grade cytology (HSIL, ASC-H, AGC) or high-risk findings (immediate CIN 3+ risk >=4.0%).
• Directed Exocervical Biopsies: Biopsy of frankly suspicious exocervical lesions may be performed during pregnancy, but carries an increased risk of brisk bleeding. Hemostasis is obtained using Monsel's solution (ferric subsulfate) or silver nitrate.
• Absolute Contraindications in Pregnancy:
  • Endocervical Curettage (ECC) is STRICTLY CONTRAINDICATED: Curettage of the endocervical canal disrupts the mucus plug, risks mechanical rupture of the amniotic membranes, introduces ascending chorioamnionitis, and triggers catastrophic preterm delivery or fetal demise.
  • Endometrial Biopsy (EMB) is STRICTLY CONTRAINDICATED: Mechanical instrumentation of the endometrial cavity disrupts the gestational sac, causing immediate pregnancy loss.
  • Diagnostic excisional procedures (LEEP/cold knife cone) are contraindicated unless invasive cervical cancer is strongly suspected on directed biopsy.
• Postpartum Follow-up: Patients with cervical precancer managed conservatively during pregnancy must undergo complete repeat colposcopy and cytology at 6 to 12 weeks postpartum.

Immunocompromised Patients (HIV, Solid Organ Transplant, Systemic Autoimmunity)

• Immunosuppressed patients have impaired cellular immune clearance, experiencing high persistent hrHPV infection rates and accelerated progression to invasive cancer.
• Screening Initiation: Screening begins at the onset of sexual debut or at the time of HIV diagnosis, even if younger than 21.
• Surveillance Protocol: Perform cervical cytology alone annually for 3 consecutive years; if all 3 results are normal, extend the screening interval to every 3 years.
• Co-Testing: Cytology and hrHPV co-testing is permitted starting at age 30, repeated every 3 years if negative.
• Lifelong Screening Mandate: Cervical cancer screening in immunocompromised patients continues lifelong and does not stop at age 65.